NCT00064584View on ClinicalTrials.gov

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

January 31, 2005

Study Completion Date

July 31, 2005

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

CT53518

Trial Locations (5)

10021

Memorial Sloan Kettering Cancer Center, New York

43210

Ohio State University Medical Center, Columbus

90095

UCLA Medical Center, Los Angeles

97201

Oregon Health Sciences University, Portland

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT00064584 - Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) | Biotech Hunter | Biotech Hunter